- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02459496
Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus (DiNA-D)
Dietary Strategies to Improve Metabolism and Body Weight in Type 2 Diabetes
Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although lifestyle modification and dietary treatment would be favourable.
The researchers therefore investigate dietary strategies such as low-carb and very-low calory diets regarding their potential to improve metabolism and body weight in (mostly) long-term T2DM patients.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although lifestyle modification and dietary treatment would be favourable.
The researchers therefore investigate dietary strategies such as low-carb diets and very-low calory diets regarding their potential to improve metabolism and body weight in (mostly) long-term T2DM patients.
An intensive intervention of 3 weeks is followed by an 11-month maintenance phase to consolidate metabolic improvements.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Berlin, Tyskland, 12203
- Rekruttering
- German Institute for Human Nutrition, Department for Clinical Nutrition
-
Kontakt:
- Stefan Kabisch, Dr. med.
- Telefonnummer: 429 030 450 514
- E-mail: stefan.kabisch@charite.de
-
Kontakt:
- Ulrike Kaiser, M.sc.
- Telefonnummer: 428 030 450 514
- E-mail: ulrike.kaiser@charite.de
-
Underforsker:
- Stefan Kabisch, Dr. med.
-
Underforsker:
- Ulrike Kaiser, M.sc.
-
-
Brandenburg
-
Bergholz-Rehbrücke, Brandenburg, Tyskland, 14458
- Ikke rekrutterer endnu
- German Institut for Human Nutrition; Department for Clinical Nutrition
-
Kontakt:
- Margrit Kemper, Dr. med.
- Telefonnummer: 033200 88 2775
- E-mail: margrit.kemper@dife.de
-
Kontakt:
- Silke Hornemann
- Telefonnummer: 033200 88 2779
- E-mail: silke.hornemann@dife.de
-
Underforsker:
- Margrit Kemper, Dr. med.
-
Underforsker:
- Silke Hornemann
-
Underforsker:
- Christiana Gerbracht, Dr.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- male and female subjects
- 18-79 years old
- type 2 diabetes
Exclusion Criteria:
- renal insufficiency
- anaemia
- immunosuppression
- previous symptomatic cancer diagnosis
- acute cardiovascular disease (stroke, coronary syndrome)
- pregnancy and lactation
- severe psychiatric disorders
- corticoid or other immunosuppressive therapy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: low-carb diet, followed by conventional DGE diet
subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory low-carb ketogenic diet (VLCKD, below 40 g carbs per day), followed by an isocaloric or moderate hypocaloric low-carb diet (below 40 kcal% carbs per day)
|
first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
|
|
Aktiv komparator: very-low calory diet, followed by conventional diet
subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory diet (VLCD; MODIFAST substitute, approx.
1200 kcal/day), followed by a conventional isocaloric or moderate hypocaloric diet under DGE guidelines
|
first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
change in insulin secretion (glucagon stimulation test)
Tidsramme: 3 weeks, 1 year
|
change in insulin secretion (glucagon stimulation test)
|
3 weeks, 1 year
|
|
change in hepatic fat content (MR-S)
Tidsramme: 3 weeks, 1 year
|
change in hepatic fat content (MR-S)
|
3 weeks, 1 year
|
|
change in insulin secretion in the mixed-meal tolerance test (MMTT) - combined parameter
Tidsramme: 3 weeks, 1 year
|
change in insulin secretion in the mixed-meal tolerance test (MMTT) - combined parameter
|
3 weeks, 1 year
|
|
change in insulin sensitivity in the mixed-meal tolerance test (MMTT) - combined parameter
Tidsramme: 3 weeks, 1 year
|
change in insulin sensitivity in the mixed-meal tolerance test (MMTT) - combined parameter
|
3 weeks, 1 year
|
|
change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter
Tidsramme: 3 weeks, 1 year
|
change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter
|
3 weeks, 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
inflammatory reaction in subcutaneous adipose tissue (SCAT analysis on protein and RNA level - IL-1; IL1beta, IL-6)
Tidsramme: 3 weeks, 1 year
|
inflammatory reaction in subcutaneous adipose tissue (SCAT analysis on protein and RNA level)
|
3 weeks, 1 year
|
|
change in parameters of peripheral - vibration threshold, thermal sensitivity and pain thresholds
Tidsramme: 3 weeks, 1 year
|
peripheral neuropathy
|
3 weeks, 1 year
|
|
change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN, MSDD)
Tidsramme: 3 weeks, 1 year
|
autonomic neuropathy
|
3 weeks, 1 year
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Andreas F.H. Pfeiffer, Prof. Dr. med., German Institute of Human Nutrition
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- DiNA-D
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Forhøjet blodtryk
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
BayerAfsluttet
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
BackBeat Medical IncIkke rekrutterer endnuHypertension, systolisk | Hypertension (HTN) | Hjertesvigt med bevaret ejektionsfraktion (HFpEF)Georgien
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
-
University Hospital, BrestIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Frankrig
-
Shanghai Zhongshan HospitalIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)